CA2448278A1 — Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
Assigned to Estetra SRL · Expires 2002-11-28 · 23y expired
What this patent protects
One aspect of the present invention relates to method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbeari ng capability in the amount effective to inhibit ovulatio…
USPTO Abstract
One aspect of the present invention relates to method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbeari ng capability in the amount effective to inhibit ovulation, wherein the estrogenic component is selected form the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1- 5 carbon atoms; each of R5, R6, R7, is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and/or a progestogenic component.
Drugs covered by this patent
- Slynd (DROSPIRENONE) · Exeltis Usa Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.